Genovac specializes in advanced antibody discovery technologies that leverage innovative immunization strategies and single B cell screening platforms. Their core technology, genetic immunization, allows for the development of antibodies directly from DNA, enabling the targeting of a wide range of proteins. Genovac offers flexibility in host species options, allowing clients to choose from various wild type and human-Ig transgenic species to enhance the likelihood of successful antibody discovery. Additionally, their automated single B cell platforms, such as Bruker’s Beacon® and Genovac Nano™, facilitate the identification of rare antibodies, while their advanced hybridoma techniques provide efficient antibody production comparable to manual methods.

Furthermore, Genovac employs cutting-edge AI technology for antibody humanization, utilizing generative deep learning algorithms to streamline the process and reduce costs and timelines. Their in-house sequencing capabilities for hybridoma and single B cell antibodies ensure reliable lead discovery, which is essential for developing therapeutic antibodies. With over 25 years of experience and a commitment to continuous improvement, Genovac has successfully completed thousands of antibody discovery projects, positioning itself as a leader in the field and a trusted partner for biotech and pharmaceutical companies facing challenging targets.

United States

A One-Stop-Shop Gene to Antibody Partner

Genovac is a contract research and manufacturing organization committed to positioning our clients for the successful development of new transformative drugs and diagnostics.

Genovac specializes in antibody discovery and production against challenging targets. Our unique combination of genetic immunization, multiple host species, multiple single B cell platforms, and state-of-the-art production facilities enables us to serve as your one-stop-shop Gene to Antibody partner.

Genovac

Company Details